{"id":4108,"date":"2023-04-20T14:24:02","date_gmt":"2023-04-20T18:24:02","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/"},"modified":"2026-11-04T04:32:25","modified_gmt":"2026-11-04T03:32:25","slug":"gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/","title":{"rendered":"GenSight Biologics Retire sa Demande d&rsquo;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le jeudi 20 avril 2023, 16h00 CEST<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd&rsquo;hui que le Comit\u00e9 des M\u00e9dicaments de Th\u00e9rapies Innovantes (<em>Committee for Advanced Therapies<\/em> ou CAT<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>) du Comit\u00e9 des M\u00e9dicaments \u00e0 Usage Humain (<em>Committee for Medicinal Products for Human Use<\/em> ou CHMP) de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) a \u00e9valu\u00e9 les donn\u00e9es pr\u00e9sent\u00e9es lors de l&rsquo;explication orale<a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a> du dossier r\u00e9glementaire europ\u00e9en de LUMEVOQ<sup>\u00ae<\/sup>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Comme le pr\u00e9voit la proc\u00e9dure d&rsquo;examen et suite aux r\u00e9ponses aux questions \u00e0 D180, une explication orale a eu lieu le 19 avril. GenSight a invit\u00e9 des experts de la NOHL<a href=\"#_ftn3\" name=\"_ftnref3\">[3]<\/a> de renomm\u00e9e mondiale, le Dr Patrick Yu-Wai-Man, PhD (Universit\u00e9 de Cambridge, Royaume-Uni) et le Dr Jos\u00e9-Alain Sahel (\u00c9cole de m\u00e9decine de l&rsquo;Universit\u00e9 de Pittsburgh, \u00c9tats-Unis), \u00e0 partager leur pratique clinique et leur point de vue sur les donn\u00e9es de LUMEVOQ<sup>\u00ae<\/sup>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Suite aux interactions avec le CAT indiquant que les donn\u00e9es fournies jusqu&rsquo;\u00e0 pr\u00e9sent ne seraient pas suffisantes pour soutenir une opinion positive sur l&rsquo;autorisation de mise sur le march\u00e9 de LUMEVOQ<sup>\u00ae <\/sup>par l&rsquo;EMA, GenSight a d\u00e9cid\u00e9 de retirer sa demande avant l\u2019obtention de l\u2019opinion finale du CAT. Cette d\u00e9cision permet \u00e0 la soci\u00e9t\u00e9 d\u2019engager des discussions avec l&rsquo;EMA sur la meilleure voie possible pour LUMEVOQ<sup>\u00ae<\/sup>\u00a0dans les semaines \u00e0 venir, le but \u00e9tant de soumettre une nouvelle demande en Europe et dans d\u2019autres pays r\u00e9pondant aux objections restantes d\u00e8s que possible. La Soci\u00e9t\u00e9 \u00e9tudie les options possibles, y compris la production de nouvelles donn\u00e9es cliniques, ce qui peut induire des d\u00e9lais importants et des co\u00fbts additionnels.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u00ab\u00a0<\/em><em>Les \u00e9quipes de GenSight ont rassembl\u00e9 un vaste ensemble de donn\u00e9es sur 252 patients atteints de ND4-NOHL et trait\u00e9s par LUMEVOQ, montrant que 70 % des patients trait\u00e9s pr\u00e9sentent une r\u00e9cup\u00e9ration visuelle, contrairement \u00e0 la r\u00e9cup\u00e9ration faible et limit\u00e9e observ\u00e9e dans l&rsquo;histoire naturelle de la maladie<\/em>\u00a0\u00bb, a d\u00e9clar\u00e9 <strong>Jos\u00e9-Alain Sahel<\/strong>, Co-fondateur de GenSight Biologics et de l\u2019Institut de la Vision, Paris, France. <em>\u00ab\u00a0<\/em><em>\u00c0 la lumi\u00e8re des r\u00e9sultats de l&rsquo;\u00e9tude, confirm\u00e9s par les donn\u00e9es de vie r\u00e9elle, LUMEVOQ est actuellement la meilleure option th\u00e9rapeutique pour les patients atteints de ND4-NOHL, \u00e9tant donn\u00e9 la diff\u00e9rence 3 fois sup\u00e9rieure de la fonction visuelle chez les patients trait\u00e9s. Il est d\u00e9cevant que l&rsquo;effet controlat\u00e9ral du traitement ait limit\u00e9 la force per\u00e7ue de ces donn\u00e9es, publi\u00e9es dans des revues \u00e0 comit\u00e9 de lecture de premier plan par des leaders dans le domaine.<\/em>\u00a0\u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab\u00a0<em>Nous d\u00e9sapprouvons l&rsquo;\u00e9valuation actuelle du CAT, et restons tr\u00e8s confiants dans le b\u00e9n\u00e9fice clinique de LUMEVOQ pour les patients atteints de NOHL, qui sont \u00e9tay\u00e9s par de nombreuses preuves issues de multiples essais cliniques et de vie r\u00e9elle\u00a0\u00bb<\/em>, a comment\u00e9 <strong>Bernard Gilly<\/strong>, Directeur G\u00e9n\u00e9ral et Co-fondateur de GenSight Biologics. \u00ab\u00a0<em>La d\u00e9cision de retirer notre demande nous permet de continuer \u00e0 travailler avec l&rsquo;EMA afin de convenir d\u00e8s que possible d&rsquo;une voie r\u00e9glementaire \u00e0 suivre. Je tiens \u00e0 remercier les communaut\u00e9s de patients pour leur soutien et \u00e0 r\u00e9affirmer notre d\u00e9termination \u00e0 apporter cette th\u00e9rapie innovante aux patients atteints de ND4-LHON qui ont besoin d&rsquo;un traitement efficace. Je tiens \u00e9galement \u00e0 remercier la communaut\u00e9 scientifique et nos \u00e9quipes pour leur engagement durable<\/em>.\u00a0\u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight confirme que la campagne de validation est en bonne voie avec son partenaire aux \u00c9tats-Unis, comme pr\u00e9vu, avec un produit lib\u00e9r\u00e9 pour l&rsquo;usage humain d&rsquo;ici la fin d\u2019ann\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La demande d&rsquo;autorisation de mise sur le march\u00e9 (AMM) de GenSight pour LUMEVOQ<sup>\u00ae<\/sup>\u00a0aupr\u00e8s de l&rsquo;EMA \u00e9tait bas\u00e9e sur la balance b\u00e9n\u00e9fice-risque \u00e9tablie par les r\u00e9sultats chez 252 patients trait\u00e9s dans le cadre d&rsquo;essais cliniques ou d&rsquo;une utilisation compassionnelle. Cet ensemble de donn\u00e9es sans pr\u00e9c\u00e9dent pour la <em>ND4<\/em>-NOHL \u00e9tablit que l&rsquo;efficacit\u00e9 de LUMEVOQ<sup>\u00ae<\/sup>\u00a0est sup\u00e9rieure \u00e0 l&rsquo;histoire naturelle et \u00e0 idebenone.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>L&rsquo;\u00e9quipe de direction de GenSight tiendra aujourd&rsquo;hui un webcast en direct \u00e0 16h30 CEST (10h30 EST) <\/strong>pour commenter cette d\u00e9cision. Le webcast se d\u00e9roulera en anglais, et une traduction simultan\u00e9e en fran\u00e7ais sera \u00e9galement disponible.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lien vers le webcast : <a href=\"https:\/\/bit.ly\/3LcxrMD\">https:\/\/bit.ly\/3LcxrMD<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La retransmission sera disponible en diff\u00e9r\u00e9 en utilisant le m\u00eame lien ci-dessus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La soci\u00e9t\u00e9 pr\u00e9sentera sa situation de tr\u00e9sorerie au 31 mars 2023 dans un communiqu\u00e9 de presse distinct plus tard dans la journ\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Le Comit\u00e9 des th\u00e9rapies innovantes (CAT) est le comit\u00e9 de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) charg\u00e9 d&rsquo;\u00e9valuer la qualit\u00e9, la s\u00e9curit\u00e9 et l&rsquo;efficacit\u00e9 des m\u00e9dicaments de th\u00e9rapie innovante (MTI) et de suivre les d\u00e9veloppements scientifiques dans ce domaine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a>\u00a0\u00a0 Apr\u00e8s le deuxi\u00e8me \u00ab\u00a0clock-stop\u00a0\u00bb, une explication orale dans laquelle le demandeur s&rsquo;adresse directement au comit\u00e9 peut \u00eatre demand\u00e9e soit par le demandeur, soit par le CHMP &#8211; https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/evaluation-medicines-step-step#clock-stop-2-section<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) et ND4 dont la mutation la plus fr\u00e9quente avec le prgnostique le plus gr\u00e2ve pour les patients NOHL.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le jeudi 20 avril 2023, 16h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd&rsquo;hui que le Comit\u00e9 des M\u00e9dicaments de Th\u00e9rapies Innovantes (Committee [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[74,76,80],"post-year":[110],"class_list":["post-4108","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-product-candidates","news-type-corporate","news-type-finance","post-year-110"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics Retire sa Demande d&#039;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics Retire sa Demande d&#039;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le jeudi 20 avril 2023, 16h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd&rsquo;hui que le Comit\u00e9 des M\u00e9dicaments de Th\u00e9rapies Innovantes (Committee [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T18:24:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-04T03:32:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\"},\"headline\":\"GenSight Biologics Retire sa Demande d&rsquo;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae\",\"datePublished\":\"2023-04-20T18:24:02+00:00\",\"dateModified\":\"2026-11-04T03:32:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/\"},\"wordCount\":961,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/\",\"name\":\"GenSight Biologics Retire sa Demande d'Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-04-20T18:24:02+00:00\",\"dateModified\":\"2026-11-04T03:32:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/04\\\/20\\\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics Retire sa Demande d&#8217;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\",\"name\":\"GenSight Biologics\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"width\":696,\"height\":696,\"caption\":\"GenSight Biologics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/8104807?trk=prof-exp-company-name\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics Retire sa Demande d'Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics Retire sa Demande d'Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics","og_description":"Paris, France, le jeudi 20 avril 2023, 16h00 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd&rsquo;hui que le Comit\u00e9 des M\u00e9dicaments de Th\u00e9rapies Innovantes (Committee [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/","og_site_name":"GenSight Biologics","article_published_time":"2023-04-20T18:24:02+00:00","article_modified_time":"2026-11-04T03:32:25+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg","type":"image\/jpeg"}],"author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a"},"headline":"GenSight Biologics Retire sa Demande d&rsquo;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae","datePublished":"2023-04-20T18:24:02+00:00","dateModified":"2026-11-04T03:32:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/"},"wordCount":961,"publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"articleSection":["Communiqu\u00e9 de presse financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/","name":"GenSight Biologics Retire sa Demande d'Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2023-04-20T18:24:02+00:00","dateModified":"2026-11-04T03:32:25+00:00","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/04\/20\/gensight-biologics-retire-sa-demande-dautorisation-de-mise-sur-le-marche-europeenne-de-lumevoq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics Retire sa Demande d&#8217;Autorisation de Mise sur le March\u00e9 Europ\u00e9enne de LUMEVOQ\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization","name":"GenSight Biologics","url":"https:\/\/www.gensight-biologics.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","width":696,"height":696,"caption":"GenSight Biologics"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/8104807?trk=prof-exp-company-name"]},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4108"}],"version-history":[{"count":1,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4108\/revisions"}],"predecessor-version":[{"id":10271,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4108\/revisions\/10271"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4108"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4108"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4108"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4108"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}